Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice

The clinical data on the efficacy and toxicity of bortezomib as treatment for multiple myeloma patients are restricted to prospective phase II studies in expert myeloma centers. Here we report a multi-institutional analysis of the efficacy and toxicity of bortezomib in patients with relapsed or refr...

Full description

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 90; no. 7; p. 996
Main Authors Wu, KL, van Wieringen, W, Vellenga, E, Zweegman, S, Lokhorst, HM, Sonneveld, P
Format Journal Article
LanguageEnglish
Published Italy 01.07.2005
Subjects
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
Antineoplastic Agents - toxicity
Boronic Acids - therapeutic use
Boronic Acids - toxicity
Bortezomib
Combined Modality Therapy
Herpes Zoster - etiology
Humans
Middle Aged
Multiple Myeloma - drug therapy
Multiple Myeloma - mortality
Pyrazines - therapeutic use
Pyrazines - toxicity
Recurrence
Time Factors
Treatment Outcome
Online AccessGet full text

Cover

More Information
Summary:The clinical data on the efficacy and toxicity of bortezomib as treatment for multiple myeloma patients are restricted to prospective phase II studies in expert myeloma centers. Here we report a multi-institutional analysis of the efficacy and toxicity of bortezomib in patients with relapsed or refractory multiple myeloma who were treated in community centers in a compassionate need program.
ISSN:0390-6078
1592-8721